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Abstract
Background:  Venous thromboembolism (VTE) following breast cancer chemotherapy is
common. Chemotherapy-induced alterations in markers of haemostasis occur during
chemotherapy. In this study we investigated the changes in serum and plasma VEGF, together with
platelet release of VEGF and related these to the development of VTE at 3 months.
Methods: Serum and plasma VEGF, together with platelet release of VEGF were measured prior
to chemotherapy and at 24 hours; four-, eight days and three months following commencement of
chemotherapy in early and advanced breast cancer patients and in age and sex matched controls.
Duplex ultrasound imaging was performed after one month or if symptomatic.
Results: Of 123 patients 9.8% developed VTE within three months. Serum and plasma VEGF were
increased in advanced breast cancer as was platelet release of VEGF. Prior to chemotherapy a 100
μg/ml increase in serum VEGF was associated with a 40% increased risk of VTE, while a 10 μg/ml
increase in plasma VEGF was associated with a 20% increased risk of VTE. Serum VEGF showed a
different response to chemotherapy in those who developed VTE.
Conclusion:  A group of patients at risk of VTE could be identified, allowing targeted
thrombopropylaxis. Whether or not the response in VEGF during chemotherapy has any
angiogenic significance remains to be elucidated.
Introduction
Venous thromboembolism (VTE) following breast cancer
chemotherapy is not uncommon. In early breast cancer,
VTE occurs in 5-10% of patients receiving chemotherapy
[1-3], with a mortality of 0.2-0.5% [1,4]. VTE rises to
approximately 18% in advanced breast cancer [5], with a
mortality of 9% [5]. Approximately two thirds of all
venous thromboemboli occur within three months of
commencing chemotherapy [3,6], however despite this,
thromboprophylaxis is rarely used [7].
Previous work has demonstrated a hypercoagulable state
in breast cancer patients, with elevated markers of coagu-
lation, including thrombin-antithrombin (TAT) [8,9],
fibrinogen [10], D-dimer [11,12] and tissue factor (TF)
[13,14].
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Several small studies have reported alterations in markers
of coagulation in response to breast cancer chemotherapy,
which support the development of a chemotherapy-
induced hypercoagulable state [15-19]. Several patho-
genic mechanisms have been suggested such as increased
expression or release of procoagulants and cytokines from
damaged cells, a direct toxic effect on vascular endothe-
lium or upregulation of platelet or monocyte activity.
The requirement for platelets in cancer metastasis was rec-
ognised about 30 years ago and it is now recognised that
platelets are an integral part of the microthrombus that is
thought to promote the arrest and lodgement of circulat-
ing tumour cells [20-22].
Platelets are numerous in the circulation and contain large
stores of factors known to be essential for angiogenesis.
Vascular endothelial growth factor (VEGF) is one such
protein that is stored in large quantities in platelet α-gran-
ules [23] and elevated circulating levels have been
observed in patients with malignancy including breast
cancer [24-26]. VEGF is pro-angiogenic and it has been
shown that VEGF secreted by megakaryocytes may con-
tribute to proliferation of vascular endothelial cells [27].
Our previous study has shown that platelets from breast
cancer patients release more VEGF per platelet than nor-
mal controls [28]
We hypothesized that platelets are functionally altered in
women with breast cancer and this may represent a possi-
ble pathophysiological mechanism for the observed VTE
during chemotherapy. In the current study we prospec-
tively followed early and advanced breast cancer patients
commencing chemotherapy to establish early alterations
in the circulating plasma and serum levels of VEGF
together with platelet release of VEGF.
Materials and methods
Patients
A total of 123 female patients [median age 52 (range, 31-
78) years] commencing chemotherapy for breast cancer
were recruited. Of these, 87 were receiving adjuvant chem-
otherapy following curative surgery, and 36 receiving
chemotherapy for radiographically-proven metastatic
breast disease (Table 1).
Control subjects
Sixty eight age matched female controls [median age 48
(range, 31-78) years], with no history of cancer acted as
control subjects.
Protocol
A prospective cohort study was undertaken. Serum vascu-
lar endothelial growth factor [sVEGF] and plasma vascular
endothelial growth factor [pVEGF]) were measured prior
to chemotherapy and at 24 hours, four-, eight days and
three months following commencement of chemother-
apy in all patients. A clinical assessment for VTE was per-
formed at the same time points. Duplex ultrasound
imaging was performed one month following commence-
ment of chemotherapy or if symptoms developed.
Table 1: Chemotherapy regimens used in breast cancer patients
Chemotherapy Regimen Number of patients
Adjuvant Regimens
5-fluorouracil, epirubicin, cyclophosphamide 65
Cyclophosphamide, methotrexate, 5-fluorouracil 15
Epirubicin, cyclophosphamide 4
Epirubicin 3
Metastatic Regimens
Docetaxol 15
Cyclophosphamide, methotrexate, 5-fluorouracil 8
Epirubicin, docetaxol 6
Vinorelbine, mitomycin 3
Epirubicin 2
5-fluorouracil, epirubicin, cyclophosphamide 1
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Blood sampling and analytical methods
Atraumatic venous blood sampling was performed at the
antecubital fossa and all specimens separated and stored
within two hours after being collected into tubes contain-
ing citrate as anticoagulant. Citrate samples were immedi-
ately taken onto ice whilst serum samples were allowed to
clot at room temperature. All samples were centrifuged at
2500 g for 20 minutes at 4°C and the plasma or serum
decanted before being stored at -80°C in 300 μl aliquots.
Platelet depleted plasma was prepared for the analysis of
VEGF as detailed: Citrated tubes were immediately
plunged into ice and taken to the laboratory were the sam-
ple was centrifuged at 4°C for twenty minutes at 3500 g.
The supernatant was removed and re-centrifuged for 20
mins at 3500 g at 4°C following which the platelet
depleted plasma (PDP) was aliquoted and the last 0.5 ml
discarded. All samples were stored at -80°C until analysis.
Platelet count was measured using the Advia 120 Haema-
tology System (Bayer Diagnostic, UK)
VEGF Assay
Serum and platelet depleted plasma VEGF were analysed
using an enzyme-linked immunosorbent assay (ELISA) by
R&D Systems®, Oxon, UK, with a sensitivity of 9 μg/ml.
In duplicate, sample (100 μl) diluted with 100 μl of assay
diluent was incubated with the capture antibody for 2
hours at room temperature. Following washing steps
(×3), 200 μl of detection antibody conjugate was added
and the assay incubated for 2 hours at room temperature.
The plate was again washed (×3) and the detection sub-
strate added and incubated for 25 minutes at room tem-
perature. Stop solution (25 μl) was added and the optical
density read at 450 nm.
Platelet VEGF
The amount of VEGF released per platelet was calculated
using the following previously validated formula [29]
Ethical approval
The study was approved by the South Manchester Local
Research Ethics Committee and all patients gave written
informed consent.
Statistical methods
Data on sVEGF and pVEGF was parametric after log con-
version and so reported as geometric mean (confidence
interval). Platelet releasate VEGF concentration was
expressed as median (range). Comparative group analysis
(early, advanced breast cancer and controls) of pre-chem-
otherapy patient values was by ANOVA, with further anal-
ysis of subgroups using Scheffe. Comparative group
analysis (VTE within three months, VTE free) of patient
values was by independent T-test. Changes in patient
serum or plasma values with chemotherapy as compared
with pre-treatment values were performed by paired T test,
however to minimise errors induced by multiple tests a
repeated measures analysis (Greenhouse Geiser correc-
tion) to compare trends over time in patients with and
without VTE was used. Comparative group analysis (VTE
within three months, VTE free) of changes in coagulation
parameters with chemotherapy as compared with pre-
treatment values were performed by analysis of covari-
ance. A significance of p < 0.05 was used. Binary logistic
regression to identify predictors of VTE was also per-
formed. Analysis was performed on baseline data, and
change from baseline. Appropriate corrections were made
for cancer stage and age.
Results
Of 123 breast cancer patients receiving chemotherapy, 12
(9.8%) developed VTE within 3 months of chemotherapy,
of which eight (66.7%) were symptomatic. Six of 36
(17%) metastatic breast cancer patients and six of 87
(6.9%) early breast cancer paients receiving adjuvant
chemotherapy developed VTE.
Baseline data: prior to chemotherapy
Prior to chemotherapy, serum and plasma VEGF were all
increased in advanced breast cancer patients compared to
controls. Further serum and plasma VEGF were increased
in advanced breast cancer compared to early breast cancer.
Platelet count was increased in advanced breast cancer
compared to controls. Calculated VEGF release per plate-
let from advanced cancer patients was elevated compared
to early breast cancer patients and the control group
(Table 2).
Baseline data: Prior to chemotherapy - Development of 
VTE
Prior to chemotherapy plasma VEGF was significantly
higher in those who developed VTE within 3 months of
commencing chemotherapy compared to those who did
not (27.8 [14.3-54.1] vs 15.4 [13.5-17.7] μg/ml, p = 0.01
[independent T-test]). Interestingly serum VEGF was not
significantly different between both groups (282 [136.5-
585.3] vs 212 [185.6-243.1] μg/ml, p = 0.2 [independent
T-test]) In addition, platelet release of VEGF did not dem-
onstrate a significant difference in those who developed
VTE within 3 months compared to those who did not.
(0.9 [0.4-1.9] vs 0.6 [0.5-0.7] VEGF μg/ml per platelet ×
109, median [range], p = 0.6 [independent T-test]). Prior
to chemotherapy however a 100 μg/ml increase in sVEGF
was associated with a 40% increased risk of VTE (P =
0.003). A 10 μg/ml increase in pVEGF was associated with
a 20% increased risk of VTE (P = 0.007)
VEGF released due to clotting       
Serum-plasma haematocri
=
×− () ( 1 t t
FBC platelet count
)Journal of Angiogenesis Research 2009, 1:7 http://www.jangiogenesis.com/content/1/1/7
Page 4 of 9
(page number not for citation purposes)
Response to chemotherapy
The mean or geometric mean (CI) of plasma and serum
VEGF together with platelet releasate VEGF (median
(range)) at baseline, 24 hours, four and eight days and
three months following chemotherapy are given in table
3, and for patients sub-divided into those developing VTE
and remaining free of VTE in tables 4 and 5 respectively.
Analysing all patients together, irrespective of subsequent
development of VTE, serum and plasma VEGF, together
with platelet release of VEGF showed a significant trend
over time (repeated measures analysis). Serum VEGF
decreased during the first 8 days, however plasma VEGF
increased (P < 0.001). By 3 months both showed trend for
increased levels (P < 0.001). In patients with and without
VTE, by four days following chemotherapy, platelet count
was reduced, however it remained within normal limits.
Levels returned to baseline by three months (Table 3).
A differing pattern of change was observed in serum VEGF
between advanced and early breast cancer patients which
was not reflected in plasma VEGF. The difference was
apparent in the first eight days following chemotherapy,
where sVEGF levels in advanced cancer showed a greater
decrease, from baseline, at 24 hours (p = 0.004) and four
days (p = 0.002) compared to early breast cancer. The dif-
ference between the trends seen in response to chemo-
therapy in advanced and early breast cancer patients was
Table 2: Baseline biomarker results prior to chemotherapy
Coagulation marker Advanced breast cancer Early breast cancer Control p ANOVA 
(Scheffe-showing paired 
comparisons)
sVEGF μg/ml, geometric 
mean (CI)[n]
344.0 (270.7-437.2)*† [35] 181.0 (155.9-210.2)* [86] 28.8 (25.3-32.8)† [61] <0.001
(*<0.001, †<0.001)
pVEGF μg/ml, geometric 
mean (CI)[n]
22.8 (17.6-29.4)*† [35] 14.2 (12.1-16.6)* [86] 15.1 (12.7-17.9)† [61] 0.004
(*0.01, †0.03)
Platelet count × 109/l, mean 
(CI) [n]
326.7* (286.9-366.5) [36] 309.6 (293.0-326.2) [87] 278.6 (257.7-299.6)* [45] 0.04
*0.05
Platelet VEGF VEGF μg/ml 
per platelet × 109
median (range) [n]
1.02*†‡ (0.17-3.53) [35] 0.53* (0.05-2.89) [83] 0.53 ‡(0.007-2.48) [45] 0.05
(*<0.001, †0.008,
‡0.002
Analysis of the difference between groups used Analysis of Variance (ANOVA). Where differences were found, further analysis (between pairs of 
groups, with respective pairs for each molecule marked with *†‡§ was performed using Scheffe. (95% Confidence interval (CI)). sVEGF = serum 
VEGF; pVEGF = plasma VEGF
Table 3: Alterations in biomarker parameters induced by chemotherapy in breast cancer patients
Procoagulant/
adhesion 
molecule
Pre-chemo [n] Day 1 (post) [n] Day 4 (post) [n] Day 8 (post) [n] 3 months (post) [n] Trend over time 
(repeated meas, GG)
sVEGF μg/ml,
geometric mean 
(CI)
218.0 (190.3-
249.6) [121]
203.4 (176.5-
234.4) [114]
158.3 (136.6-
183.4) [114]
154.3 (132.5-
179.8) [116]
236.7 (205.0-273.4) 
[109]
p < 0.001
pVEGF μg/ml,
geometric mean 
(CI)
16.4 (14.2-18.8) 
[120]
14.9 (13.2-16.9) 
[115]
16.3 (14.0-18.0) 
[112]
20.5 (18.3-13.0) 
[114]
21.6 (18.8-24.9) 
[106]
p < 0.001
Platelet count × 
109/l
Mean (CI)
314 (298.4-
330.9) [123]
306 (287.2-325) 
[99]
263.3 (249.7-
276.8) [108]
242.3 (227.3-
257.2) [117]
310 (285.0-334) 
[112]
P < 0.001
Platelet VEGF 
VEGF μg/ml per 
platelet × 109
median (range) 
[n]
0.62 (0.54-0.72)
[120]
0.61 (0.52-0.71)
[99]
0.51 (0.43-0.61)
[108]
0.53 (0.45-0.64)
[114]
0.72 (0.62-0.83)
[106]
P < 0.001Journal of Angiogenesis Research 2009, 1:7 http://www.jangiogenesis.com/content/1/1/7
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no longer apparent by three months (p = 0.2). The rapid
decrease in sVEGF levels, in advanced breast cancer, as an
early response to chemotherapy was not mirrored by
pVEGF levels. (Table 6).
Platelet release of VEGF showed a significant trend in
reponse to chemotherapy. There was a decline in platelet
release of VEGF by day 4 and 8 (P < 0.001) increasing to
above pre-chemotherapy levels by 3 months (Table 3).
The alteration in platelet release of VEGF was significantly
different in advanced breast cancer (Table 6). Although
both groups appeared to show a decline in platelet release
of VEGF initially following chemotherapy this was not sig-
nificant in advanced cancer even at 24 hours (P = 0.15),
compared to early cancer (P < 0.001 at day 8)
When patients who subsequently developed VTE were
compared to patients who remained free of VTE (Tables 4
and 5), serum VEGF showed marked alterations in
response to chemotherapy in those with and without VTE
at three months. Serum VEGF shows a more marked
increase in patients subsequently developing VTE (p =
0.01), even when corrections are made for cancer stage
(Tables 4 and 5). There was a marked decrease in pVEGF,
but not sVEGF, within 24 hours of commencing chemo-
therapy, in patients developing VTE compared to patients
remaining free of VTE (change from pre-chemotherapy
levels to 24 hours: -8.3 and -0.9 μg/ml, n = 11 and 104, p
= 0.04). A decrease in pVEGF within 24 hours was associ-
a t e d  w i t h  a n  i n c r e a s e d  r i s k  o f  V T E ,  w i t h  a  1 0  μg/ml
decrease from baseline, at 24 hours, increasing the risk of
VTE by 25% (p = 0.05).
Table 4: Alterations in biomarker parameters induced by chemotherapy in breast cancer patients developing VTE within three 
months of chemotherapy
Coagulation marker Pre-chemo [n] Day 1 
(post chemo) [n]
Day 4
 (post chemo) [n]
Day 8 
(post chemo) [n]
3 months 
(post chemo) [n]
sVEGF μg/ml,
geometric mean (CI)
282.6 (136.5-585.3) 
[11]
267.8 (136.5-525.4) 
[11]
220.1 (110.7-437.3) 
[11]
226.0 (116.3-439.2) 
[11]
358.8 (116.3-774.2) 
[9]
pVEGF μg/ml,
geometric mean (CI)
27.8 (14.3-54.1) [12] 19.5 (10.4-36.6) [11] 19.0 (9.4-38.3) [11] 23.4 (13.2-41.5) [11] 18.7 (13.7-25.5) [9]
Platelet count × 109/l 
mean (CI)
342.5 (265.8-419.2) 
[12]
338.9 (246.4-431.4) 
[10]
269.6 (225.5-313.8) 
[11]
274 (216.8-331.2) 
[11]
386.2 (238.3-534.1) 
[10]
Platelet VEGF VEGF 
μg/ml per platelet × 
109
median (range) [n]
0.89 (0.42-1.87)
[11]
0.89 (0.47-1.68)
[10]
0.86 (0.39-1.86)
[11]
0.83 (0.39-1.75)
[11]
1.02 (0.53-1.97)
[9]
Table 5: Alterations in biomarkers induced by chemotherapy in breast cancer patients remaining free of VTE within three months of 
chemotherapy
Coagulation marker Pre-chemo [n] Day 1 (post chemo) 
[n]
Day 4 (post chemo) 
[n]
Day 8 (post chemo) 
[n]
3 months (post 
chemo) [n]
sVEGF μg/ml,
geometric mean (CI)
212.4 (185.6-243.1) 
[110]
197.5 (171.1-228.0) 
[103]
152.8 (131.7-177.4) 
[103]
148.3 (126.8-173.3) 
[105]
228.0 (197.4-263.4) 
[100]
pVEGF μg/ml,
geometric mean (CI)
15.4 (13.5-17.7) [108] 14.5 (12.9-16.4) [104] 16.0 (13.7-18.7) [101] 20.2 (18.0-22.7) [103] 21.9 (18.8-25.5) [97]
Platelet count × 109/l, 
mean (CI)
311.6 (295.2-328) 
[111]
302.4 (283.4-321.4) 
[89]
262.5 (248.1-277) 
[97]
239 (223.4-254.5) 
[106]
302.5 (279.6-325.5) 
[102]
Platelet VEGF VEGF 
μg/ml per platelet × 
109
median (range) [n]
0.61 (0.52-0.71)
[108]
0.58 (049-0.69)
[89]
0.49 (0.41-0.58)
[97]
0.52 (0.43-0.62)
[103]
0.70 (0.61-0.81) [97]Journal of Angiogenesis Research 2009, 1:7 http://www.jangiogenesis.com/content/1/1/7
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Platelet release of VEGF during chemotherapy did not
demonstrate a significantly different response in those
who developed VTE within 3 months compared to those
who did not (P = 0.6).
Discussion
Consistent with previously published literature, sVEGF
and pVEGF levels in this study are significantly elevated in
advanced breast cancer patients [29]. Interestingly, pVEGF
levels in the early breast cancer group (following apparent
complete surgical resection) are comparable to controls.
Previous literature report increased levels in early breast
cancer patients prior to surgery [30,31].
The higher VEGF seen in serum compared to plasma sam-
ples, is consistent with previous studies reporting platelet
release of VEGF as the main source of serum VEGF
[32,33]. The much lower levels of pVEGF may represent
ongoing platelet release of VEGF in addition to other
sources, including tumour cells. Consistent with previ-
ously published literature, sVEGF and pVEGF levels in this
study are significantly elevated in advanced breast cancer
patients [29]. Several studies report elevated serum and
plasma VEGF in early cancer patients, prior to curative sur-
gery [29,34].
In the first eight days following chemotherapy, the
increase in pVEGF is matched by a decrease in sVEGF. This
may reflect increased platelet release of VEGF as a
response to chemotherapy, with a consequent reduction
in stored levels of VEGF in the platelet α-granules [35].
This is supported by the reduction in calculated VEGF per
platelet in the eight days following chemotherapy. The
decrease seen in serum VEGF is particularly marked in
advanced cancer (both absolute sVEGF, and VEGF
released per platelet). This implies the platelet response to
chemotherapy is altered in the presence of cancer. As
platelet content of VEGF increases, this must be either due
to increased platelet (megakaryocyte) production of VEGF
[36] or platelet scavenging of circulating VEGF produced
from other cellular sources [37,38]. The lack of difference
between advanced and early breast cancer response to
chemotherapy may provide evidence to refute previous
theories that increased platelet content of VEGF in cancer
is due to platelet scavenging of tumour VEGF [35,39].
Previous research has shown that platelet lysates from
breast cancer patients have increased VEGF concentra-
tions compared to controls [39]. In this study we show
that this is limited to advanced cancer patients. A previous
study by Salgado and colleagues shows increased VEGF
release per platelet in advanced cancer compared to early
cancer (prior to surgery), and early cancer compared to
Table 6: Table showing the chemotherapy induced changes in serum VEGF and platelet release of VEGF in advanced and early breast 
cancer
Procoagulant Group Baseline Day 1 Day 4 Day 8 3 Months Significant Difference in 
Trend
i) pre-chemo to day 8
ii)Pre-chemo to 3 
months
sVEGF
μg/ml
Geometric Mean 
(CI) [n]
ABC 344 (271-437) 
[35]
287 (219-376) 
[33]
240 (182-317) 
[33]
253 (196-327) 
[33]
344 (248-477) 
[26]
i) 0.01*
ii) 0.2*
EBC 181 (156-210) 
[86]
177 (151-207) 
[81]
134 (114-157) 
[81]
127 (107-151) 
[83]
211 (181-246) 
[83]
i) 0.01**
ii) 0.2**
VEGF 
released
per platelet
μg/ml/platelet
Geometric mean 
(CI) [n]
ABC 1.02 (0.8-1.30) 
[35]
0.92 (0.68-
1.23) [28]
0.85 (0.61-
1.17) [30]
0.92 (0.72-
1.19) [31]
1.03 (0.77-
1.39) [25]
i) 0.007*
II) 0.03*
EBC 0.53 (0.45-
0.62) [82]
0.51 (0.42-
0.63) [67]
0.43 (0.35-
0.52) [73]
0.43 (0.34-0.
53) [78]
0.65 (0.54-
0.77) [78]
i) 0.007**
ii) 0.03**
sVEGF = serum vascular endothelial growth factor (VEGF)
ABC = advanced breast cancer
EBC = early breast cancer
*Significant difference in trend compared to early breast cancer
**Significant difference in trend compared to advanced breast cancerJournal of Angiogenesis Research 2009, 1:7 http://www.jangiogenesis.com/content/1/1/7
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control. However in their study they fail to correct for
background circulating VEGF (pVEGF) [35]. Previous
work from our group [28] showed VEGF release from
platelets was also greater in early breast cancer patients
compared to controls, but did not study advanced breast
cancer patients, although this study used a different meth-
odology and smaller number of patients.
After an initial decrease in platelet VEGF content, possibly
due to VEGF release stimulated by chemotherapy, the pos-
sible increase in platelet VEGF content in advanced cancer
only, suggests an important store of this angiogenic mol-
ecule in active cancer. The profound effect of chemother-
apy on platelet VEGF content in early breast cancer
suggests an initial early release of VEGF by platelets in
response to chemotherapy, hence depleting stores. This
appears to be followed by a reactive increase in VEGF stor-
age, which is mirrored by the absolute platelet count. Ver-
heul and co-workers, in a study of 27 breast cancer
patients receiving chemotherapy, reported an initial
thrombocytopenia followed by a strong platelet rebound
coinciding closely with a sVEGF peak. However, by not
correcting this for background (plasma) levels of VEGF, or
calculating VEGF per platelet, they concluded that sVEGF
simply reflects platelet count [40]. The data from this
present study suggests not just a chemotherapy-induced
rebound in platelet count (ie decrease, followed by steady
increase), but also a similar decrease and then steady
increase in individual platelet content of VEGF, irrespec-
tive of platelet count. This implies an alteration in platelet
function. The significance of this in relation to angiogen-
esis however remains unknown.
Prior to chemotherapy, plasma VEGF was increased in
patients subsequently developing VTE, with a trend for
increased sVEGF levels in the VTE patient group. Other
investigators have reported sVEGF and pVEGF correlate
with the haemostatic markers TAT, fibrinogen and D-
dimer [41]. Kim and co-workers report an association
between increased VEGF per platelet and portal vein
thrombosis in hepatocellular carcinoma, however in this
study the authors do not correct for background (plasma)
VEGF levels that may contribute to the reported sVEGF per
platelet levels [42]. As previously discussed, sVEGF largely
consists of VEGF released from platelets, but pVEGF may
also represent a significant tumour contribution. The
strong association of pVEGF but not sVEGF with VTE may
reflect patients with a greater tumour release of VEGF hav-
ing an increased risk of VTE.
Of the procoagulants we have studied, only pVEGF dem-
onstrates an early altered response to chemotherapy in
patients developing VTE, compared to those without VTE.
The marked reduction in pVEGF, but not sVEGF at 24
hours in the VTE group, suggests rapid uptake of back-
ground VEGF in the hypercoagulable patients. Whether
this uptake is by cancer cells, or perhaps more likely, by
altered function of platelets, remains to be established.
There was no difference in pre-chemotherapy platelet
count, or platelet release of VEGF, in all breast cancer
patients with and without subsequent VTE. This supports
the findings of Leibovitch, who although reporting reac-
tive thrombocytosis as a common finding following
major urological surgery, found no association with
thromboembolic complications [43]. Pedersen also
found no association between thrombocytosis in primary
lung cancer, and development of VTE [44]. However,
thrombocytosis, above the normal range, occurred in the
advanced breast cancer patients that subsequently devel-
oped VTE. Goodnough, in 159 advanced breast cancer
patients, found no incidence of thrombocytosis, prior to
chemotherapy, in patients developing VTE compared to
patients without VTE. However in this analysis, Good-
nough et al [5] included all patients developing VTE, even
patients with VTE occurring after completion of treat-
ment. Elevated levels of platelet microparticles (which
correlate with platelet activation) in vivo have been
reported for patients with activated coagulation and fibri-
nolysis [45], however research is minimal on platelet
release of angiogenic molecules as a predictor of VTE.
In conclusion, raised pVEGF, prior to chemotherapy in
patients developing VTE, may point to the procoagulant
trigger for cancer-induced VTE. The increased baseline
pVEGF, but not sVEGF, in patients developing VTE
implies tumour VEGF rather than platelet VEGF is the
important procoagulant here. However, the rapid reduc-
tion in pVEGF following chemotherapy, in the VTE group,
suggests an increased VEGF uptake, either by tumour, or
perhaps more likely, by platelets. This study provides evi-
dence that a clinically useful profile could be produced to
identify patients at increased risk of VTE. With such a pro-
file, a trial of targeted anticoagulant prophylaxis could be
developed.
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